Classifications: antineoplastic; antimetabolite, purine antagonist; Therapeutic: antineoplastic; antimetabolite
Pregnancy Category: D
1 mg/mL injection
Cladribine is a synthetic antineoplastic agent with selective toxicity toward certain normal and malignant lymphocytes and
monocytes. It accumulates intracellularly, preventing repair of single-stranded DNA breaks and ultimately interfering with
cellular metabolism and DNA synthesis.
Cladribine is cytotoxic to both actively dividing and quiescent lymphocytes and monocytes, inhibiting both DNa synthesis
Treatment of hairy cell leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphomas.
Advanced cutaneous T-cell lymphomas, acute myeloid leukemia, autoimmune hemolytic anemia, mycosis fungoides.
Hypersensitivity to cladribine; severe bone marrow suppression; pregnancy (category D).
Hepatic or renal impairment; previous radiation therapy or chemotherapy. Safety and efficacy in children not established.
Route & Dosage
|Hairy Cell Leukemia
Adult: IV 0.09 mg/kg/d by 7 d continuous infusion
Chronic Lymphocytic Leukemia/Non-Hodgkin's Lymphoma
Adult: IV 0.1 mg/kg/d by 7 d continuous infusion repeated monthly
- Solutions for cladribine should not be mixed with any other IV drugs or additives, nor administered through an IV line used
for other drugs or solutions.
- Use disposable gloves and protective clothing when handling the drug.
- Wash immediately if skin contact occurs.
PREPARE: IV Infusion (single daily dose): Add the required dose to 500 mL of NS. IV infusion (7-day dose): The calculated dose of cladribine is injected into an
infusion reservoir using a 0.22 micron filter. An amount of bacteriostatic NS is added through a 0.22 micron filter to bring
the total to 100 mL. (Note: Reservoir usually prepared by the pharmacist.)
ADMINISTER: IV Infusion (single daily dose): Distribute evenly over ordered time (i.e., 2 h or 24 h). IV infusion (7-d dose): Give through a central line and control by a pump device (e.g., Deltec pump) to deliver 100 mL evenly over 7 d.
INCOMPATIBILITIES Solution/additive: Do not mix with any other diluents or drugs.
- Diluted solutions of cladribine may be stored refrigerated for up to 8 h prior to administration.
- Store unopened vials in refrigerator [2°8° C (36°46° F)], and protect from light.
Adverse Effects (≥1%)CNS:
Headache, dizziness. GI:
. Hematologic: Myelosuppression (neutropenia), anemia, thrombocytopenia
. Metabolic: Fever. CNS:
Headache, dizziness. Urogenital:
Elevated serum creatinine
Additive risk of bleeding with anticoagulants
, platelet inhibitors
Therapeutic effect 10 d to 4 mo. Duration:
725+ mo. Distribution:
Crosses placenta; distributed into breast milk. Metabolism:
In malignant leukocytes
, cladribine is phosphorylated to active forms, which are subsequently incorporated into cellular
Initial 35 min, terminal 6.7 h.
Assessment & Drug Effects
- Monitor vital signs during and after drug infusion. Fever (>100° F) is common during the 5th to 7th day in patients
with hairy cell leukemia, and severe fever (>104° F) may develop within the first month of therapy.
- Lab tests: Frequent hematologic studies; periodic serum creatinine and liver function tests.
- Closely monitor hematologic status; myelosuppression is common during the first month after starting therapy.
- Monitor for and report S&S of infection. Note that within the first month, fever may occur in the absence of infection.
- With high doses of cladribine, monitor for neurologic toxicity (paraparesis/quadriparesis) and acute nephrotoxicity.
Patient & Family Education
- Be fully informed regarding adverse responses to the drug.
- Understand the need for close follow-up during and after treatment with the drug.